Vamorolon (2) – Agamree®
Duchenne muscular dystrophy, aged ≥ 2 to < 4 years
Characteristics
| Start date | 15.06.2026 |
|---|---|
| Resolution | 03.12.2026 – active procedure |
| INN | Vamorolon |
| Brand name | Agamree® |
| Pharm. company | Santhera Pharmaceuticals GmbH |
| G-BA Procedure ID | D-1345 |
| Therapeutic area | Musculoskeletal system diseases Orphan |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Vamorolon (2) | Agamree® | Santhera Pharmaceuticals GmbH | Duchenne muscular dystrophy, aged ≥ 2 to < 4 years | n.d. | active procedure Orphan | |
| Vamorolon (1) | Agamree® | Santhera Pharmaceuticals GmbH | Duchenne muscular dystrophy, ≥ 4 years | 740–3,670 | 100% Hint for non-quantifiable additional benefit Orphan |
<< List of all resolutions